Vir Biotechnology, Inc.
VIR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001706431
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
237
- −15 vs. Q1 2026
- Total value $1.49B
Superinvestors holding VIR
0
- None of the superinvestors held VIR at the end of Q2 2026.
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by VIR insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Jun 1, 2026 | Napolitano JanetDirector | SSaleCommon Stock | −3.2K | $9.45 | −$30.24K | 21.22K | −13.1% | SEC10b5-1 |
| Jun 2, 2026 | Jun 1, 2026 | Sabatini BrentSVP, Chief Accounting Officer | SSaleCommon Stock | −379 | $9.45 | −$3.58K | 61.9K | −0.6% | SEC10b5-1 |
| May 4, 2026 | May 1, 2026 | SATO VICKI LDirector | SSaleCommon Stock | −22K | $10.05 | −$221.1K | 1.08M | −2.0% | SEC10b5-1 |
| Apr 7, 2026 | Apr 6, 2026 | De Backer MariannePresident and CEO | SSaleCommon Stock | −72.56K | $9.16 | −$664.64K | 948.15K | −7.1% | SEC10b5-1 |
| Apr 2, 2026 | Apr 1, 2026 | SATO VICKI LDirector | SSaleCommon Stock | −22K | $9.07 | −$199.54K | 1.1M | −2.0% | SEC10b5-1 |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in VIR at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,678,283 | $210.71M | 0.00% | +2,679,954+14.9% | Added |
| ARCH Venture Management, LLC | 12,694,163 | $129.35M | 11.76% | −222,500−1.7% | Reduced |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 11,495,215 | $117.14M | 0.01% | +2,279,638+24.7% | Added |
| SB INVESTMENT ADVISERS (UK) LTD | 10,948,093 | $111.56M | 1.46% | 00.0% | Unchanged |
| STATE STREET CORP | 9,964,151 | $101.53M | 0.00% | +2,823,057+39.5% | Added |